References
- Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC, Damrauer S, Tsao PS, Klarin D, Baras A, Reid J, et al. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat Commun. 2019;10:1499. doi:https://doi.org/10.1038/s41467-019-09480-8.
- Sanchez-Roige S, Palmer AA, Fontanillas P, Elson SL, Adams MJ, Howard DM, Edenberg HJ, Davies G, Crist RC, Deary IJ, et al. Genome-wide association study meta-analysis of the alcohol use disorders identification test (AUDIT) in two population-based cohorts. Am J Psychiatry. 2019;176:107–18. doi:https://doi.org/10.1176/appi.ajp.2018.18040369.
- Bierut LJ, Goate AM, Breslau N, Johnson EO, Bertelsen S, Fox L, Agrawal A, Bucholz KK, Grucza R, Hesselbrock V, et al. ADH1B is associated with alcohol dependence and alcohol consumption in populations of European and African ancestry. Mol Psychiatry. 2012;17:445–50. doi:https://doi.org/10.1038/mp.2011.124.
- Crist RC, Doyle GA, Nelson EC, Degenhardt L, Martin NG, Montgomery GW, Saxon AJ, Ling W, Berrettini WH. A polymorphism in the OPRM1 3ʹ-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J. 2016;18:173–179. doi:https://doi.org/10.1038/tpj.2016.89.
- Hancock DB, Levy JL, Gaddis NC, Glasheen C, Saccone NL, Page GP, Hulse GK, Wildenauer D, Kelty EA, Schwab SG, et al. Cis-expression quantitative trait loci mapping reveals replicable associations with heroin addiction in OPRM1. Biol Psychiatry. 2015;78:474–84. doi:https://doi.org/10.1016/j.biopsych.2015.01.003.
- Xu J, Lu Z, Xu M, Pan L, Deng Y, Xie X, Liu H, Ding S, Hurd YL, Pasternak GW, et al. A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the mu opioid receptor gene OPRM1 via hnRNPH interactions. J Neurosci. 2014;34:11048–66. doi:https://doi.org/10.1523/JNEUROSCI.3986-13.2014.
- Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology. 2013;38:2003–10. doi:https://doi.org/10.1038/npp.2013.99.
- Crist RC, Phillips KA, Furnari MA, Moran LM, Doyle GA, McNicholas LF, Cornish JW, Kampman KM, Preston KL, Berrettini WH. Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder. Pharmacogenomics J. 2019;19:260–68. doi:https://doi.org/10.1038/s41397-018-0065-x.
- Kranzler HR, Lynch KG, Crist RC, Hartwell E, Le Moigne A, Laffont CM, Andorn AC. A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder. Int J Neuropsychopharmacol. 2020;24:89–96. doi:https://doi.org/10.1093/ijnp/pyaa069.
- Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C, Ferraro TN, Hakonarson H, Kampman KM, Dackis CA, et al. Case-control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend. 2013;127:122–28. doi:https://doi.org/10.1016/j.drugalcdep.2012.06.023.
- Sharafshah A, Fazel H, Albonaim A, Omarmeli V, Rezaei S, Mirzajani E, Ajamian F, Keshavarz P. Association of OPRD1 gene variants with opioid dependence in addicted male individuals undergoing methadone treatment in the north of Iran. J Psychoactive Drugs. 2017;49:242–51. doi:https://doi.org/10.1080/02791072.2017.1290303.
- Roussotte FF, Jahanshad N, Hibar DP, Sowell ER, Kohannim O, Barysheva M, Hansell NK, McMahon KL, de Zubicaray GI, Montgomery GW, et al. A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: replication in elderly and young populations. Hum Brain Mapp. 2014;35:1226–36. doi:https://doi.org/10.1002/hbm.22247.
- Arnoult N, Correia A, Ma J, Merlo A, Garcia-Gomez S, Maric M, Tognetti M, Benner CW, Boulton SJ, Saghatelian A, et al. Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN. Nature. 2017;549:548–52. doi:https://doi.org/10.1038/nature24023.
- Zhao H, Zhuang Y, Li R, Liu Y, Mei Z, He Z, Zhou F, Zhou Y. Effects of different doses of X-ray irradiation on cell apoptosis, cell cycle, DNA damage repair and glycolysis in HeLa cells. Oncol Lett. 2019;17:42–54.
- Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011;12:652–69. doi:https://doi.org/10.1038/nrn3119.
- Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, Cassingena A, Rusconi F, Esposito A, Nichelatti M, et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res. 2013;19:2265–72. doi:https://doi.org/10.1158/1078-0432.CCR-12-3518.
- Mou Z, Hyde TM, Lipska BK, Martinowich K, Wei P, Ong CJ, Hunter LA, Palaguachi GI, Morgun E, Teng R, et al. Human obesity associated with an intronic SNP in the brain-derived neurotrophic factor locus. Cell Rep. 2015;13:1073–80. doi:https://doi.org/10.1016/j.celrep.2015.09.065.
- Tolnay M, Vereshchagina LA, Tsokos GC. Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specific DNA-binding protein. Biochem J. 1999;338:417–25. doi:https://doi.org/10.1042/bj3380417.
- Tolnay M, Baranyi L, Tsokos GC. Heterogeneous nuclear ribonucleoprotein D0 contains transactivator and DNA-binding domains. Biochem J. 2000;348:151–58. doi:https://doi.org/10.1042/bj3480151.
- Dempsey LA, Hanakahi LA, Maizels N. A specific isoform of hnRNP D interacts with DNA in the LR1 heterodimer: canonical RNA binding motifs in a sequence-specific duplex DNA binding protein. J Biol Chem. 1998;273:29224–29. doi:https://doi.org/10.1074/jbc.273.44.29224.
- Walker JR, Corpina RA, Goldberg J. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature. 2001;412:607–14. doi:https://doi.org/10.1038/35088000.
- Mimori T, Hardin JA. Mechanism of interaction between Ku protein and DNA. J Biol Chem. 1986;261:10375–79. doi:https://doi.org/10.1016/S0021-9258(18)67534-9.
- Camara-Clayette V, Thomas D, Rahuel C, Barbey R, Cartron JP, Bertrand O. The repressor which binds the −75 GATA motif of the GPB promoter contains Ku70 as the DNA binding subunit. Nucleic Acids Res. 1999;27:1656–63. doi:https://doi.org/10.1093/nar/27.7.1656.
- Shi L, Qiu D, Zhao G, Corthesy B, Lees-Miller S, Reeves WH, Kao PN. Dynamic binding of Ku80, Ku70 and NF90 to the IL-2 promoter in vivo in activated T-cells. Nucleic Acids Res. 2007;35:2302–10. doi:https://doi.org/10.1093/nar/gkm117.
- Nolens G, Pignon JC, Koopmansch B, Elmoualij B, Zorzi W, De Pauw E, Winkler R. Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines. Breast Cancer Res. 2009;11:R83. doi:https://doi.org/10.1186/bcr2450.
- De Zio D, Bordi M, Tino E, Lanzuolo C, Ferraro E, Mora E, Ciccosanti F, Fimia GM, Orlando V, Cecconi F. The DNA repair complex Ku70/86 modulates Apaf1 expression upon DNA damage. Cell Death Differ. 2011;18:516–27. doi:https://doi.org/10.1038/cdd.2010.125.
- Willis DM, Loewy AP, Charlton-Kachigian N, Shao JS, Ornitz DM, Towler DA. Regulation of osteocalcin gene expression by a novel Ku antigen transcription factor complex. J Biol Chem. 2002;277:37280–91. doi:https://doi.org/10.1074/jbc.M206482200.
- Vogel H, Lim DS, Karsenty G, Finegold M, Hasty P. Deletion of Ku86 causes early onset of senescence in mice. Proc Natl Acad Sci U S A. 1999;96:10770–75. doi:https://doi.org/10.1073/pnas.96.19.10770.
- Li GC, Ouyang H, Li X, Nagasawa H, Little JB, Chen DJ, Ling CC, Fuks Z, Cordon-Cardo C. Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. Mol Cell. 1998;2:1–8. doi:https://doi.org/10.1016/S1097-2765(00)80108-2.
- Mazumder S, Plesca D, Kinter M, Almasan A. Interaction of a cyclin E fragment with Ku70 regulates Bax-mediated apoptosis. Mol Cell Biol. 2007;27:3511–20. doi:https://doi.org/10.1128/MCB.01448-06.
- Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C, Frye R, Ploegh H, Kessler BM, Sinclair DA. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell. 2004;13:627–38. doi:https://doi.org/10.1016/S1097-2765(04)00094-2.
- Schubert C, O’Donnell P, Quan J, Wendland J, Xi H, Winslow A, Domenici E, Essioux L, Kam-Thong T, Airey D. BrainSeq: neurogenomics to drive novel target discovery for neuropsychiatric disorders. Neuron. 2015;88:1078–83. doi:https://doi.org/10.1016/j.neuron.2015.10.047.
- Ardlie KG, Deluca DS, Segre AV, Sullivan TJ, Young TR, Gelfand ET, Trowbridge CA, Maller JB, Tukiainen T, Lek M. The GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648–60. doi:https://doi.org/10.1126/science.1262110.
- Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT, Colantuoni EA, Elkahloun AG, Herman MM, Weinberger DR, et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature. 2011;478:519–23. doi:https://doi.org/10.1038/nature10524.
- Bakalkin G, Yakovleva T, Hurd YL, Nussenzweig A, Li GC, Terenius L. Autoantigen Ku in the brain. Developmentally regulated expression and subcellular localization. Neuroreport. 1998;9:2147–51. doi:https://doi.org/10.1097/00001756-199806220-00044.
- Lake BB, Ai R, Kaeser GE, Salathia NS, Yung YC, Liu R, Wildberg A, Gao D, Fung HL, Chen S, et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science. 2016;352:1586–90. doi:https://doi.org/10.1126/science.aaf1204.